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Uracil–Tegafur (UFT), an oral fluorinated pyrimidine chemotherapeutic agent, has been used for adjuvant chemotherapy in curatively
resected colorectal cancer patients. Past trials and meta-analyses indicate that it is somewhat effective in extending survival of patients
with rectal cancer. The objective of this study was to perform a reappraisal of randomised clinical trials conducted in this field. We
designed an individual patient-based meta-analysis of relevant clinical trials to examine the benefit of UFT for curatively resected rectal
cancer in terms of overall survival (OS), disease-free survival (DFS), and local relapse-free survival (LRFS). We analysed individual
patient data of five adjuvant therapy randomised clinical trials for rectal cancer, which met the predetermined inclusion criteria. These
five trials had a combined total of 2091 patients, UFT as adjuvant chemotherapy compared to surgery-alone, 5-year follow-up,
intention-to-treat-based analytic strategy, and similar endpoints (OS and DFS). In a pooled analysis, UFT had significant advantage
over surgery-alone in terms of both OS (hazard ratio, 0.82; 95% confidence interval (CI), 0.70–0.97; P¼0.02) and DFS (hazard ratio,
0.73; 95%CI, 0.63–0.84; Po0.0001). This individual patient-based meta-analysis demonstrated that oral UFT significantly improves
both OS and DFS in patients with curatively resected rectal cancer.
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Colorectal cancer accounts for 10–15% of all cancers and is the
second leading cause of cancer deaths in developed countries
(Pisani et al, 1993). In Japan alone, nearly 56000 new cases are
diagnosed and this disease causes 36000 deaths every year
(Statistics and information department, Ministry of Health and
Welfare, 1996). Surgical treatment is the primary management of
colorectal cancers, with 75–80% of the patients being operable at
the time of diagnosis (Boring et al, 1991; Vernaba et al, 1994).
However, even if a curative resection is performed, those patients
with regional lymph node involvement (Dukes’ C, Stage III) have a
40–50% 5-year survival rate.
Recently, in the field of Stage III colon cancer treatment,
adjuvant chemotherapy by 5-fluorouracil (5-FU)/levamisole was
proved to be superior to surgery-alone therapy, and then various
5-FU/leucovorin (LV) regimens were confirmed to be effective
from the results of numerous large-scale randomised trials and
from the pooled analysis of clinical trials (Wolmark et al, 1993;
International Multicentre Pooled Analysis of Colon Cancer Trials
(IMPACT) investigators, 1995; O’Connell et al, 1997). In 2004,
results from the Multicenter International Study of Oxaliplatin/5-
FU/Leucovorin in the Adjuvant Treatment of Colon Cancer
(MOSAIC) trial demonstrated that combination chemotherapy
with 5-FU/LV (de Gramont regimen) plus oxaliplatin was
significantly superior to 5-FU/LV alone (Andre ´ et al, 2004). With
regard to adjuvant chemotherapy for colon cancer, therefore, solid
evidence has been accumulated from relevant clinical trials, and
steady evolution of the new treatment modalities has been
achieved.
However, the situation is still uncertain focusing on adjuvant
therapy for rectal cancer. Despite apparently curative surgery,
rectal cancer recurs in more than 55% of the patients, including
local recurrence rates of 25% (Vernaba et al, 1994). Despite the
recommendation of the consensus conference by the National
Institute of Health (NIH consensus conference, 1990) that
concluded that adjuvant radiotherapy and chemotherapy should
be given to all patients with locally advanced rectal cancer, recent
findings by a large-scale randomised trial and meta-analysis have
failed to prove significant benefit of radiotherapy for survival
(Fisher et al, 1988; Vernaba et al, 1994). In this regard, the quest
for an effective adjuvant treatment with a robust advantage on the
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soutcome of resected rectal cancer remain an important task for
gastrointestinal oncologists.
In Japan, mesorectal excision is standard surgical procedure.
Radiotherapy is not routinely performed as adjuvant therapy.
In Japan, adjuvant therapy after resection of colorectal cancer
was developed primarily using oral fluorinated pyrimidines (O-
FPs). A meta-analysis of three old trials (Sakamoto et al, 1999) and
a more sophisticated analysis of four recent pivotal randomised
trials (Sakamoto et al, 2004) demonstrated a statistically significant
benefit of O-FPs on the outcome of colorectal cancers over surgery
alone. However, the survival benefit shown in that meta-analysis
was more pronounced in colon cancers. The risk reduction in
terms of rectal cancer was only 8% and the result of those previous
meta-analyses that analysed various types of oral fluorinated
pyrimidine clinical trials was not sufficient to show a significant
effect on survival.
Uracil–tegafur (UFT) is one of the O-FPs. In colon cancer, the
majority of recurrences occurred in the liver, whereas in rectal
cancer many recurrences occurred in the lung and locally in
addition to the liver. Treatment effect may thus differ between
colon cancer and rectal cancer. As the previous meta-analysis, two
trials of UFT in patients with rectal cancer have been reported. The
present study focused on rectal cancer, which lacked a clear-cut
survival benefit in our previous meta-analysis. Unlike oral
fluoropyrimidines such as carmofur and capecitabine, the
formulation of UFT includes a dihydropyrimidine dehydrogenase
inhibitor (Diasio, 1999), designed to enhance the bioavailability of
FU. This combination of uracil and tegafur was shown, in an
animal tumour system, to increase the anti-tumour activity
compared with tegafur alone (Ooi et al, 2001). UFT also produced
an enhanced intratumoural concentration of fluorinated pyrimi-
dine, 5–10 times greater than that achieved with Tegafur alone
(Fukunaga et al, 1987). Preclinical studies established that the
optimal molar ratio of uracil to Tegafur is 4:1, which resulted in
the highest 5-FU tumour: blood and tumour: normal tissue
partition coefficients (Kawaguchi et al, 1980). UFT has now been
clinically tested for lung cancer (Kato et al, 2004), breast cancer
(Noguchi et al, 2005), and for gastric cancer (Kinoshita et al, 2005)
in an adjuvant setting in Japan. Recently, UFT has also been tested
in Western countries, regarding its efficacy for both advanced and
curatively resected colon cancer (Carmichael et al, 2002; Douillard
et al, 2002; Lembersky et al, 2006).
Here, we present an individual patient data meta-analysis of five
centrally randomised trials recently performed in Japan to
compare rectal cancer patients treated with UFT, with the
surgery-alone control group. This meta-analysis includes data
from more than 2000 patients and therefore provides a more
reliable assessment of the effect of UFT on the survival, disease-
free survival (DFS), and local relapse-free survival (LRFS) of the
patients with rectal cancer than is available from any of the
individual studies.
PATIENTS AND METHODS
Selection of trials
Trials that randomly assigned patients to either long-term (12
months) administration of UFT or surgery-alone treatment after
curative resection of rectal cancer were eligible for meta-analysis.
The randomisation technique used in these trials was the
centralised randomisation that precluded the possibility of prior
knowledge of the treatment to be allocated.
Five relevant trials identified as Japanese Foundation for Multi-
disciplinary Treatment of Cancer (JFMC) 7-1 (Kodaira et al, 1998),
JFMC15-1, JFMC15-2 (Watanabe et al, 2004), Tokai Adjuvant
Chemotherapy Study Group for Colorectal Cancer (TAC–CR) (Kato
et al, 2002), and National Surgical Adjuvant Study of Colorectal
Cancer (NSAS-CC) (Akasu et al, 2006) were included in the meta-
analysis involving a total of 2091 patients. In trials JFMC7-1, JFMC15-
1, and JFMC 15-2, patients who were randomly assigned to the
experimental group received intravenous mitomycin C (6mgm
 2)a t
1 week and once monthly for 6 months. In the JFMC15-1 and 15-2
trials, patients who were randomly assigned to the experimental
group additionally received an induction course of intravenous 5-FU
(250mgdaily
 1) during 7 postoperative days (Table 1).
Protocol and data collection for the meta-analysis
In December 2003, a protocol for the meta-analysis, describing the
study rationale, statistical methods, and guidelines for publication,
was distributed to the principal investigators of the five trials.
Investigators were asked to provide individual data for every
randomised patient, whether eligible or not, assessable or not, and
Table 1 Details of the randomized controlled trials included in the individual patient data meta-analysis
Category JFMC7-1 JFMC15-1 JFMC15-2 TAC-CR NSAS-CC Total
Additional chemotherapy Mitomycin C Mitomycin C+FU IV Mitomycin C+FU IV None None —
Radiotherapy None None None None None —
UFT dose/day 400mg 400mg 400mg 400mg 600mg
a —
Period 12 months 12 months 12 months 24 months 12 months —
Dates of accrual 1986–1988 1989 1990 1991–1994 1996–2001 —
No. of patients 834 447 391 143 276 —
Duration of accrual, months 35 24 24 36 54 —
Sex, No. of patients (male–female ratio)
Male 521 (62.4%) 260 (58.1%) 244 (62.4%) 93 (65.0%) 167 (60.5%) 1285 (61.4%)
Female 313 (37.6%) 187 (41.9%) 147 (37.6%) 50 (35.0%) 109 (39.5%) 806 (38.9%)
Duke’s stage, No. of patients
A 135 67 62 12 0 276
B 326 175 139 53 0 693
C 373 205 189 78 276 1121
Median age 57 60 59 62 58 58
Upper age limit, years 70 75 75 75 75 —
JFMC¼Japanese Foundation for Multidisciplinary Treatment of Cancer; NSAS-CC¼National Surgical Adjuvant Study of Colorectal Cancer; TAC–CR¼Tokai Adjuvant
Chemotherapy for Colorectal Cancer; UFT¼Uracil–Tegafur.
a400mgm
 2day
 1 for 5 days every 7 days.
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were as follows: patient identification, date of surgery, eligibility,
allocated treatment by random assignment, age, sex, primary
tumour site, Dukes’ stage, induction chemotherapy, dates of
recurrence, death, or last visit. Disease-free survival was calculated
from the date of surgery to the date of recurrence, second primary
cancer or death, whichever occurred first. Survival was calculated
from the date of surgery to the date of death, regardless of the
cause of death. Local relapse-free survival was calculated from the
date of surgery to the date of local recurrence. Data from patients
with only distant recurrence and those who were died without
recurrence were censored. Patients enrolled in these trials had
been followed up for 5–7 years. Toxicity data were not collected,
because detailed analysis of side effects can be found in the
published reports of the individual trials (Kodaira et al, 1998; Kato
et al, 2002; Watanabe et al, 2004; Akasu et al, 2006).
All investigators and the Clinical Trial Committee of all the trials
agreed to join in the meta-analysis. Individual patient data were
received by the independent secretariat by February 2004 and
October 2006.
Pretreatment patient characteristics
All 2091 patients had curatively resected rectal cancer without
evidence of distant metastasis by diagnostic imaging criteria or by
macroscopic examination of the abdominal organs during surgery.
Patients with severe postoperative complications were excluded
from all trials, as were patients with any previous chemotherapy or
radiotherapy or with a synchronous or metachronous second
cancer. Median patient age was 61 years at the time of random
assignment. The male/female ratio was approximately 3:2.
Performance status was less than 2 on the Japan Clinical Oncology
Group scale for all patients.
Statistical analysis
The method used for the meta-analysis and the format for the
presentation of the results have been described in detail elsewhere
(Advanced Colorectal Cancer Meta-Analysis Project, 1992). All
analyses were based on individual patient data. Treatment effects
on DFS, LRFS, and survival were first estimated within each trial
and then combined using classical meta-analytic methods (Color-
ectal Cancer Collaborative Group, 2001). Treatment effects were
displayed as hazard ratios. These ratios were estimated by
univariate Cox’s proportional model as relative risks of having
an event in the UFT group as compared with having the same
event in the surgery-alone control group. A ratio less than unity
indicates benefit from UFT, and this benefit is statistically
significant when the 95% confidence interval (CI) of the ratio
does not include unity. The overall effect of treatment was assessed
through a w1
2 d.f. and the heterogeneity between five trials through
a w4
2 d.f. (Colorectal Cancer Collaborative Group, 2001). Additional
analyses were carried out to determine which of the following
prognostic features, if any, were predictive of the treatment effect:
Dukes’ stage (A vs B vs C), sex (male vs female), and age (three
groups of increasing age). Tests for interaction were applied to
detect departures from the homogeneity of treatment effects.
Multivariate analyses were performed with the use of the Cox
proportional hazards regression model for DFS, LRFS, and survival
to assess the robustness of the observed effects to adjustments for
important covariates and the magnitude of interaction between
treatment effect and covariate (Advanced Colorectal Cancer Meta-
Analysis Project, 1992). All P-values resulted from use of two-sided
statistical tests. The significance level was set at 5% for all tests.
RESULTS
Survival
Survival hazard ratios for all the trials are presented in Figure 1.
The overall hazard ratio was 0.82 (95% CI, 0.70–0.97; P¼0.02)
with no significant heterogeneity between the treatment effects in
different trials (w4
2 for heterogeneity¼4.31; P¼0.37). UFT showed
significant effect on survival of curatively resected rectal cancers
with a 5-year survival benefit of approximately 5%.
Figure 2 shows the breakdown of the survival hazard ratio
stratified by various patient characteristics. There was a slight
trend toward larger treatment benefits in earlier Dukes’ stages
(Hazard ratio; Dukes’ A¼0.60, Dukes’ B¼0.79, Dukes’ C¼0.86)
but heterogeneity tests did not show any significant difference
(w2
2¼1.41; P¼0.495). There was no statistically significant
difference in sex (w1
2 for interaction¼1.62; P¼0.204) or age (w2
2
for interaction¼0.22; P¼0.898).
Figure 3 shows survival curves by treatment and disease stage.
These curves confirm the hazard ratio analysis shown in Figure 2
and point to favourable effects of UFT in all Dukes’ stages.
Disease-free survival
Disease-free survival hazard ratios are presented in Figure 4 for all
the trials. These figure show a somewhat larger effect of treatment
on DFS than on survival, with an overall DFS ratio of 0.73 (95%CI,
Study Control
Hazard Ratio
(Treatment / Control)
Total 
Test for heterogeneity
P = 0.37
No. Events / No. Entered
Treatment
HR; 0.82
Treatment better
Treatment effect P = 0.02
Control better
0                   1 2
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34%
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Figure 1 Survival hazard ratios by individual trial (Abbreviations: O/N¼observed number of events/number of patients; O–E¼Observed minus
Expected number of events; V¼variance of (O–E); Hazard Redn¼hazard reduction; SE¼standard error of hazard reduction).
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demonstrating some heterogeneity among the treatment effects in
different trials (w4
2 for heterogeneity¼7.85; P¼0.097). Addition-
ally, random effect model assuming the variation between trials
was applied. The results of the random effect model still revealed
highly significant differences owing to the relatively high effect in
TAC–CR and NSAS-CC trials.
Figure 5 lists the DFS hazard ratios by various patient and
treatment characteristics.
Figure 6 shows DFS curves by treatment and disease stage. These
curves again point to benefits of UFT in Dukes’ A, B and C stages.
Roughly identical effect extended across all Dukes’ stages: the DFS
benefits at 5 years in terms of risk reduction were 0.42, 0.33, 0.23.
Local relapse free survival
The overall hazard ratio was 0.68 (95%CI, 0.53–0.87; P¼0.0026),
and demonstrating some heterogeneity among the treatment
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Figure 2 Survival hazard ratios by patient and treatment characteristics (Abbreviations as in Figure 1).
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Figure 3 Survival curves by tumour stage and by treatment.
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seffects in different trials (w4
2 for heterogeneity¼8.82; P¼0.0658).
UFT also showed significant effect on LRFS of curatively resected
rectal cancers.
DISCUSSION
Extensive preclinical and clinical research led to the optimisation
of 5-FU administration, with 5-FU bolus in combination with LV
as standard therapy both in metastatic disease (Advanced Colo-
rectal Cancer Meta-Analysis Project, 1992) and after curative
resection of Stage III (Dukes’ C) colon cancer (International
Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT)
investigators, 1995; O’Connell et al, 1997; Wolmark et al, 1999).
However, the toxicity of bolus 5-FU/LV regimen, especially the risk
of haematologic toxicity and mucositis, could not have been
negligible.
Continuous-infusion 5-FU modulated by LV, utilised mostly in
European countries, showed somewhat better efficacy and
definitely better tolerance than bolus 5-FU in advanced diseases
(de Gramont et al, 1997; Meta-Analysis Group In Cancer, 1998a,b;
Schmoll et al, 2000). In the adjuvant setting, one of the conti-
nuous regimens (LV5-FU2) was shown to have low toxicity than
the bolus regimen, but no difference was shown in terms of
survival (Andre ´ et al, 2003). Recently, combination of continuous
5-FU/LV and oxaliplatin (FOLFOX 4) was demonstrated to have
significant effect on DFS, and is now considered as the standard
adjuvant regimen for colon cancer in the Western world.
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Control better
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Figure 4 Disease-free survival hazard ratios by individual trial (Abbreviations as in Figure 1).
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Figure 5 Disease-free survival hazard ratios by patient and treatment characteristics (Abbreviations as in Figure 1).
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perspectives. Oral fluorinated pyrimidines may mimic continuous
regimens without its technical inconvenience and deterring
patients’ quality of life. In patients with advanced colorectal
cancer, the efficacy of UFT (typical and most prescribed O-FP)
plus oral LV (Carmichael et al, 2002; Douillard et al, 2002) or of
capecitabine alone (Hoff et al, 2001; Van Cutsem et al, 2001) seems
comparable in terms of the efficacy with significantly less
significant severe haematologic toxicities and/or stomatitis. The
risk of severe hand-foot syndrome is lower in UFT than with
capecitabine, but the risk of severe diarrhoea and other gastro-
intestinal symptoms is higher in UFT and in UFT/oral LV
treatment for Western patients.
In Japan, UFT have been administered for many years especially
for patients with curatively resected colorectal cancers. For some
unknown reason, severe gastrointestinal toxicities are much less
frequent in Japanese patients, and patients usually prefer oral
chemotherapy especially in an adjuvant setting (Borner et al,
2002).
Furthermore, with regard to rectal cancer, it is a difficult
objective for a clinical trial to accrue enough patients, compared to
colon cancer, and despite the fact that several attempts of
determining a standard adjuvant treatment for rectal cancer,
almost no clinical trial has succeeded in showing a relevant
survival benefit of adjuvant treatment, except one with preopera-
tive radiotherapy (Swedish Rectal Cancer Trial, 1997).
In this context, several Japanese groups conducted randomised
clinical trials comparing UFT with surgery alone for curatively
resected rectal cancers. Five such trials were identified after a
meticulous search, and are included in the present meta-analysis.
This meta-analysis was restricted to trials that had been
randomised centrally and from which no patient had been
excluded for any reason. It represents the largest series of properly
randomly assigned patients receiving the single oral adjuvant O-FP
agent, that is, UFT, for rectal cancer comparing with patients
receiving no therapy after curative tumour resection.
This meta-analysis found a statistically significant benefit of
UFT with regard to overall survival (OS) (hazard ratio¼0.82;
P¼0.02) as well as DFS (hazard ratio¼0.73; Po0.0001), and LRFS
(hazard ratio¼0.68; P¼0.0026). As can seen by comparing the
data in Figures 1 and 4, the data from the NSAS-CC and TAC–CR
study show benefits that are, apparently, larger than the others.
As shown in Table 1, the dosage and duration of treatment
with UFT in the NSAS-CC and TAC–CR trials differed from
those in the other three trials; the dose intensity of UFT was higher
in the former two trials. Several studies have reported that a high-
dose intensity of UFT improves survival in patients given
postoperative adjuvant chemotherapy for gastric cancer (Sugimachi
et al, 1997; Danno et al, 2001). The higher dose intensity of UFT in
the NSAS-CC and TAC–CR trials may have influenced the
outcomes.
Most of the Japanese rectal cancer patients did not receive pre-
or postoperative radiotherapy in any of the trials. Although
radiotherapy has been considered one of the standard adjuvant
treatments in the Western countries, significant survival benefit
has not been shown with reproducibility (Wolmark et al, 2000;
Colorectal Cancer Collaborative Group, 2001). The ostensible
advantage of adjuvant radiotherapy is to decrease local recurrence
of rectal cancers. As compared with postoperative chemo-
radiotherapy, preoperative chemoradiotherapy does not improve
OS, but inhibits local recurrence and reduces toxicity (Sauer et al,
2004). In our study, however, LRFS was also significantly better in
the UFT group compared to surgery alone group. As far as our
results are concerned, UFT might also be useful in preventing local
recurrence in Japanese patients who usually do not receive
radiotherapy in an adjuvant setting.
Also, there is still a debate whether adjuvant chemotherapy for
early stage rectal cancer is feasible (Buyse and Piedbois, 2001). In
terms of numbers needed to treat, these benefits imply that
approximately 20 patients need to be treated for one more patient
to survive 5 years, and approximately 10 to be treated for one fewer
patient to suffer a cancer recurrence within 5 years, regardless of
disease stage. Our results show that the therapy is beneficial in
Stage II patients not only Stage III patients with nodal involvement
(Mamounas et al, 1999; Gray et al, 2004). As for early stage disease,
further investigations are needed to assess potential benefits of
treatment because events were infrequent and hazard ratios were
small.
Regardless of the disease stage and patient background
characteristics, there is a need for further trials involving UFT
and new agents that are effective in advanced disease, such as
irinotecan, oxaliplatin, and monoclonal antibodies.
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Figure 6 Disease-free survival curves by tumour stage and by treatment.
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